A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is
Supplementary Table 1. Summary of safety outcomes over 52 weeks for patients with MDD receiving open-label adjunctive brexpiprazole 0.5-3 mg/day Safety population (n=2,938) Incidence of treatment-emergent suicidality,* % (n/N) C-SSRS Suicidal ideation 5.5 (161/2,938) C-SSRS Suicidal behavior 0.2 (7/2,938)doi:10.1097/jcp.0000000000001034 fatcat:sv7zuyib75ghhfyb7gf7zu6iwe